

Availability of the 2023 Universal Registration Document

Bordeaux, April 25, 2024 – 6:00 p.m. CEST – Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces the publication of its 2023 Universal Registration Document (URD) approved by the French Financial Markets Authority (*Autorité des Marchés Financiers* (AMF)) on April 24, 2024, under number R.24-004.

The Universal Registration Document 2023 includes in particular:

- The 2023 annual financial report;
- The statutory auditor's reports;
- Information on the statutory auditor's fees;
- Information relating to corporate social responsibility.

The URD can be consulted and downloaded on the Company's website under the heading [Investors / Documentation](#), as well as on the AMF website (<https://www.amf-france.org>).

Financial Agenda:

- Annual General Meeting, June 4, 2024
- 2024 Half-Year Results, September 16, 2024

About AELIS FARMA

Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling-Specific inhibitors of the CB₁ receptor of the endocannabinoid system (CB₁-SSi). CB₁-SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB₁ hyperactivity made by the team led by Dr. Pier Vincenzo Piazza, the Company's CEO, when he was the director of the Neurocentre Magendie of the INSERM in Bordeaux. By mimicking this natural mechanism, CB₁-SSi appear to selectively inhibit the disease-related activity of the CB₁ receptor without disrupting its normal physiological activity. CB₁-SSi have consequently the potential to provide new safe treatments for several brain diseases.

Aelis Farma is currently developing two first-in-class clinical-stage drug candidates: AEF0117 for the treatment of cannabis use disorder (CUD), currently being tested in a phase 2b study in the United States; and AEF0217 for cognitive disorders, including those of Down Syndrome (Trisomy 21), currently in a phase 1/2 study in Spain in people with Down syndrome. The Company also has a portfolio of new innovative CB₁-SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB₁ receptor.

Aelis Farma draws on the talents of more than 25 highly qualified employees.

For more information, visit www.aelisfarma.com and follow us on [LinkedIn](#) and [Twitter](#).



ISIN: FR0014007ZB4

Ticker: AELIS

B Compartment of Euronext Paris

Contacts

AELIS FARMA

Arsène Guekam
Chief Corporate Development Officer
contact@aelisfarma.com

NewCap

Dusan Oresansky / Aurélie Manavarere
Investor Relations
aelis@newcap.eu
+33 1 44 71 94 92

NewCap

Arthur Rouillé
Media Relations
aelis@newcap.eu
+33 1 44 71 00 15

Disclaimer

Forward-looking statements

Some information contained in this press release are forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, or achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document approved by the Autorité des Marchés Financiers on April 24, 2024, under number R.24-004.

These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.